Media headlines about CytomX Therapeutics (NASDAQ:CTMX) have been trending somewhat positive recently, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CytomX Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.1917195476242 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

NASDAQ:CTMX traded down $0.69 during trading hours on Friday, reaching $18.82. The company had a trading volume of 464,146 shares, compared to its average volume of 310,708. CytomX Therapeutics has a 52 week low of $16.26 and a 52 week high of $35.00. The company has a market cap of $853.41 million, a PE ratio of -16.22 and a beta of 0.81.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The firm had revenue of $21.34 million for the quarter, compared to analysts’ expectations of $16.48 million. CytomX Therapeutics had a negative net margin of 44.46% and a negative return on equity of 74.84%. equities analysts predict that CytomX Therapeutics will post -1.5 earnings per share for the current year.

CTMX has been the topic of several recent research reports. ValuEngine downgraded CytomX Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Tuesday, July 10th. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. SunTrust Banks began coverage on CytomX Therapeutics in a research note on Friday, June 1st. They set a “buy” rating and a $38.00 price objective on the stock. Finally, HC Wainwright began coverage on CytomX Therapeutics in a research note on Thursday. They set a “buy” rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. CytomX Therapeutics currently has an average rating of “Buy” and a consensus target price of $37.67.

In other CytomX Therapeutics news, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $22.56, for a total value of $67,680.00. Following the sale, the chief financial officer now owns 8,928 shares in the company, valued at approximately $201,415.68. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sean A. Mccarthy sold 13,052 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $21.86, for a total transaction of $285,316.72. Following the completion of the sale, the insider now owns 95,115 shares in the company, valued at approximately $2,079,213.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 41,629 shares of company stock worth $967,572. Corporate insiders own 8.50% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

See Also: Penny Stocks, What You Need To Know

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.